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Abstract
Background:  Oral squamous cell carcinoma (OSCC) represents the most common oral
malignancy. Despite recent advances in therapy, up to 50% of the cases have relapse and/or
metastasis. There is therefore a strong need for the identification of new biological markers able
to predict the clinical behaviour of these lesions in order to improve quality of life and overall
survival. Among tumour progression biomarkers, already known for their involvement in other
neoplasia, a crucial role is ascribed to the urokinase-type plasminogen activator receptor (uPAR),
which plays a multiple role in extracellular proteolysis, cell migration and tissue remodelling not
only as a receptor for the zymogen pro-uPA but also as a component for cell adhesion and as a
chemoattractant. The purpose of this study was to gain information on the expression of uPAR in
OSCC and to verify whether this molecule can have a role as a prognostic/predictive marker for
this neoplasia.
Methods: In a retrospective study, a cohort of 189 OSCC patients was investigated for uPAR
expression and its cellular localization by immunohistochemistry. As standard controls, 8 normal
oral mucosal tissues free of malignancy, obtained from patients with no evidence or history of oral
cavity tumours, were similarly investigated. After grouping for uPAR expression, OSCCs were
statistically analyzed for the variables age, gender, histological grading (G), tumour size, recurrence,
TNM staging and overall survival rate.
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Results:  In our immunohistochemical study, 74 cases (39.1%) of OSCC showed a mostly
cytoplasmic positivity for uPAR, whereas 115 were negative. uPAR expression correlated with
tumour differentiation grade and prognosis: percentage of positive cases was the greatest in G3
(70.4%) and patients positives for uPAR expression had an expectation of life lower than those for
uPAR negatives.
Conclusion: The results obtained in this study suggest a role of uPAR as a potential biomarker
useful to identify higher risk subgroups of OSCC patients.
Background
Oral squamous cell carcinoma (OSCC) is one of the most
common cancers, with a world incidence of more than
350 000 new cases per year [1]. In spite of improved ther-
apeutic procedures, the mortality rate for this neoplasia
has not changed appreciably in the Western world for over
20 years: the 5-year overall survival does not exceed 55%
which is mainly caused by locally aggressive tumour phe-
notypes. At the moment, the most important prognostic
factor for OSCC is efficacy of surgical treatment which
consists in "complete" excision of the primary lesions and
includes intra-operative histopathological examination of
peri-tumoral tissues to confirm the presence of tumour-
free excision margins. Nevertheless, within 24 months, up
to 50% of the cases have relapse and/or metastasis, the
possible explanations being inappropriate histopatholog-
ical evaluation or the presence of "occult" cells that are
undetectable by means of the currently used diagnostic
procedures. Furthermore, the removal of these tumours
frequently needs massive surgical resections that impair
important physiological functions such as speech and
swallowing. Thus, there is a strong need for the identifica-
tion of molecular markers that could be correlated with
tumour characteristics and able to predict the biological
behaviour of an individual lesion in order to differentiate
tumours requiring more aggressive therapeutic and/or
surgical treatments. This can improve quality of life, dis-
ease-free and overall survival of OSCC patients. Even
though considerable efforts have been made in this direc-
tion, a sensitive and specific marker useful to clinicians to
direct preventive and therapeutic management
approaches for OSCC has not been identified yet.
Transition from non invasive to invasive carcinoma imply
a complex biological change that enables cancer cells to
detach from the epithelial cells and to assume the tran-
scriptional program characteristic of mesenchymal cells,
in order to acquire the attributes of invasiveness and
motility. The most important effectors of these complexes
changes are proteolytic systems active on component of
the extracellular matrix.
Among them, the proteolytic cascade system of plasmino-
gen activation, directed by the urokinase-type plasmino-
gen activator (uPA) and its receptor (uPAR), has long been
recognized as the one that performs a central role in can-
cer invasion, mainly due to uPAR's capability to concen-
trate and increase uPA's proteolitic activity on cell surface.
In active movement cells, uPAR is localized at the migra-
tion front thereby focusing uPA activity where proteolysis
is required. Furthermore, uPAR has been recognized as a
multifunctional protein connected to a number of non-
proteolysis-related processes, such as cell adhesion and
migration, chemotaxis and tissue remodelling, emphasiz-
ing the importance of this molecule in cell invasion [2].
uPAR expression levels in tumour sections and their prog-
nostic values have been studied in several human neo-
plasms, such as colon, breast, ovarian, stomach and lung
carcinomas [3-5]. These studies have shown that high
uPAR expression levels correlate with poor prognosis,
therefore making it as a potential biological marker corre-
lated to tumour progression and aggressiveness. Increased
uPAR expression has also been found in head and neck
squamous cell carcinomas (HNSCC), although without
any significant correlation to staging parameters [6].
Instead, an immunohistochemical analysis of 34 primary
oral cancers showed a correlation between uPAR expres-
sion and both cancer invasion and secondary regional
lymph node metastasis [7]. A more recent study of 20
cases of incipient OSCC reported immunohistochemical
localization of uPAR in both stromal cells and neoplastic
cell islands located at the invasive front of the lesion [8].
This is in line with the emerging concept that morpholog-
ical and functional characteristics of the invasive tumour
front underlie the biological aggressiveness of oral cancer
[9]. These results suggest a possible role of uPAR in early
oral cancer invasion. Therefore, we sought to extend the
analysis of uPAR expression in a larger cohort of OSCC
patients in order to gain more information on its rele-
vance for the clinical outcome of these tumours.
Methods
Tissue samples and patient characteristics
Histological material was obtained from the files of the
Institute of Pathological Anatomy and Histopathology,
Polytechnic University of the Marche Region, Ancona,
Italy. Samples were taken from oral cavity squamous cell
carcinomas and adjacent normal mucosa of 189 patients
consecutively recruited between 1990 and 2002. In allBMC Cancer 2008, 8:220 http://www.biomedcentral.com/1471-2407/8/220
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cases the specimen provided the first observation of the
disease. The patients included 143 males and 46 females.
They ranged between 33 and 95 years of age at the time of
admission (mean 66.11 ± 0.9 SE); 85 of them had neck
nodes and none had any evidence of distant metastasis.
Median follow-up was 53.13 months (± 3.4 SE). The diag-
nosis in this investigation was performed by an expert oral
pathologist (C.R.) on the basis of the 2003 World Health
Organization (WHO) classification and according to the
2003 revision of the TNM system [10]. Histological grad-
ing was done by focusing on the stage of invasion which
expresses the infiltrative characteristics of the front of the
lesion. On the basis of this classification, the specimens
were subdivided into four groups: squamous cell carci-
noma grade 1 (G1) (77 cases), grade 2 (G2) (68 cases)
and grade 3 (G3) (44 cases), and normal oral mucosal tis-
sues free of malignancy (8 cases) obtained from patients
with no evidence or history of oral cavity tumours (Table
1).
The use of archived human tissues conformed to an
informed protocol that had been reviewed and approved
by the institutional review board of the Polytechnic Uni-
versity of the Marche Region, Italy.
Immunohistochemistry
uPAR expression was evaluated in 4-μm-thick tissue sec-
tions cut from formalin-fixed, paraffin-embedded speci-
mens using a labelled streptavidin-biotin kit (Dako
Corporation, Carpinteria, California, U.S.A.). One section
of each case, stained with haematoxylin-eosin, was used
to confirm the histopathological diagnosis. Only those
sections that showed sufficient epithelium to assess 500
cells were considered for this study. Antigen retrieval was
done by covering the deparaffinized tissue sections with
0.05% Pronase (Dako Corporation, Carpinteria, Califor-
nia, U.S.A.) at room temperature for 10 min in a humidity
chamber. After washing in Tris-HCl buffer (0.5 M, pH
7.6), endogenous peroxidase was blocked with 3% hydro-
gen peroxide in water for 10 min. Next, slides were rinsed
in water and Tris-HCl buffer for several minutes before
being incubated for 24 h at 4°C with a mixture of two
anti-uPAR monoclonal antibodies (R2 and R4, diluted to
1  μg/ml in Tris-HCl, whose specificity in recognising
uPAR has been well established [11]). The slides were
then washed three times with Tris-HCl buffer and incu-
bated for 30 min with biotinylated goat anti-rabbit and
goat anti-mouse immunoglobulins. After extensive wash-
ing, slides were incubated with peroxidase labelled
streptavidin, subsequently developed using 3,3'-dia-
monobenzidine tetrahydrochloride (Sigma, St. Louis,
Missouri, U.S.A.) and 0.02% hydrogen peroxide. Finally,
specimens were counterstained with Mayer's hematoxy-
lin. In all cases, the specificity of the reaction was checked
by incubating adjacent sections of each sample with an
isotype-matched monoclonal antibody (MOPC-21,
Sigma) used at the same final concentration as that of the
anti-uPAR R2 and R4.
A mean percentage of positive tumour cells was deter-
mined by examining 500 neoplastic cells. Samples were
classified as uPAR positive if expression was detected in
more than 1% of the cancerous tissue. uPAR- stained sec-
tions were also evaluated in terms of cell pattern of stain-
ing. This feature refers to the staining of individual cells
and it was defined as membranous when uPAR staining
revealed predominant membrane distribution, whereas
was defined as cytoplasmic when strong positivity was
observed in both the cytoplasm and membrane.
Statistics
Data were analysed using GraphPad Prism software ver-
sion 5.00 for Windows (GraphPad Software, San Diego
California USA, http://www.graphpad.com). Significant
differences (p < 0.05) between groups were determined
using the χ2 – test (Fisher's exact test was used instead of
χ2 when only two groups were considered) and Kruskal –
Wallis statistic (Mann – Whitney test was used instead of
Kruskal – Wallis when only two groups were considered).
Survival curves were analyzed according to the Kaplan-
Meier method, and for differences between curves the p
value was calculated by the log-rank test. A p value of less
than 0.05 was accepted as statistically significant.
Results
Immunohistochemical analysis of cancer tissue samples
using specific uPAR antibodies revealed that 74 out of 189
carcinomas were positive (39.1%). The cell pattern of
staining, valued in the neoplastic and stromal compo-
nents of invasive front and inflammatory peritumoral
Table 1: Patient Characteristics
Group No. of cases 2003 WHO classification TNM stage (2003 revision)
I II III IV
17 7 G 1 4 1 1 7 8 1 1
26 8 G 2 2 8 1 3 8 1 9
34 4 G 3 1 0 9 9 1 6
48 n o r m a l  m u c o s aBMC Cancer 2008, 8:220 http://www.biomedcentral.com/1471-2407/8/220
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component, was mostly cytoplasmic (Fig. 1). The analysis
of 8 normal oral mucosal tissues, free of malignancy, did
not reveal any positivity (data not shown).
The obtained data were then used to carry out a statistical
analysis, correlating uPAR expression with clinicopatho-
logical parameters. The results of this evaluation are
shown in Table 2.
χ2 analysis indicated that uPAR expression statistically
correlated with grading. In fact, the number of positive
cases was the highest in G3 (31 cases, 70.4%), than in G1
and G2 (20.8% and 39.7% respectively). Moreover, in G3
the percentage of cells expressing uPAR was significantly
increased (Table 2).
To investigate whether uPAR expression was of prognostic
relevance, survival analysis was performed and overall
survival was calculated using the log-rank statistics. Inter-
estingly, Kaplan-Meier plot, comparing overall survival
rates for patients with tumours displaying positive immu-
nohistochemical staining for uPAR versus patients with
uPAR negative OSCC (Fig. 2A), revealed a statistically sig-
nificant association with prognosis (log-rank test, p  =
0.0053). Patients with uPAR positive tumours had a lower
life expectancy than those with uPAR negative tumours.
Kaplan-Meier curves correlating uPAR expression with
grading showed a statistical correlation between overall
survival and grade 1 with a shorter overall survival for
uPAR positives patients (log-rank test, p = 0.0447) (Fig.
2B), while no correlation was found with grade 2 and 3
uPAR expression in OSCC Figure 1
uPAR expression in OSCC. A: Strong cytoplasmic positivity of neoplastic epithelial cells in poorly differentiated OSCC (G3) (× 
250). B: Weak cytoplasmic positivity of epithelial cells of invasive front in moderately differentiated OSCC (G2) (× 200). C: 
Focal strong positivity in stromal and inflammatory peritumoral cells in moderately differentiated OSCC (G2) (× 160). D: Neg-
ativity of an adjacent section incubated with an isotype-matched monoclonal control antibody (× 400).BMC Cancer 2008, 8:220 http://www.biomedcentral.com/1471-2407/8/220
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(Fig. 2C, D).
Correlation between OSCC that stained positively for
uPAR and other variables of potential prognostic signifi-
cance was studied using the χ2 test. No statistically signif-
icant association was observed between uPAR expression
and age, gender, tumour size, staging and primary tumour
recurrence (Table 2).
Discussion
Several attempts have been undertaken to improve prog-
nosis in cancer patients and to establish predictive factors
related to tumour biology. Presently, for OSCC there are
not reliable prognostic factors able to predict the biologi-
cal behaviour of the tumour or eventual clinical outcome.
Clinical stage has some predictive value as does histologi-
cal grade. However, these parameters suffer from lack of
standardization and considerable observed-related varia-
bility. There is therefore a strong need for the develop-
ment of new diagnostic tools that can help the clinician to
define the most appropriate management for the individ-
ual patient.
Features regarding cells at the invading margins of the
tumours are probably of higher prognostic value than fea-
tures within other parts of the tumours. Several molecular
events of importance for tumour spread like gains and
losses of adhesion molecules, secretion of proteolytic
enzymes, increased cell proliferation and initiation of
angiogenesis, occur at the tumour-host interface, where
cancer cells receive specific signals from the nearby reac-
tive stroma and undergo an epithelial-mesenchimal tran-
Table 2: Statistical analysis of uPAR expression and associated clinicopathological findings in OSCCs
Variables No. UPAr  
expression
n. (%)
Chi-square 
P <0.05
Mean Standard 
deviation
Standard 
error
Mann  
Whitney
P <0.05
Multiple Comparison Test
Cases 189 74 (39.1)
Age
< 65 years 78 25 (32) No 39 19.8 14 No
> 65 years 111 49 (44) 0.0989° 55.5 9.192 6.5 0.0854
Sex
Male 143 56 (39.1) No 71.5 21.92 15.5 No
Female 46 18 (39.1) 1.0000° 23 7.071 5 0.7103
Grading Dunn's Multiple Comparison Test 
Difference in rank sum P < 0.05
G1 77 16 (20.8) Yes 3.052 8.515 0.9703 Yes G1 vs G2 -16,14 No
G2 68 27 (39.7) < 0.0001 5.103 12.09 1.466 < 0.0001* G1 vs G3 -50,00 Yes
G3 44 31 (70.4) 14.77 20.52 3.094 G2 vs G3 -33,87 Yes
Size
< 1.5 cm 48 17 (35.4) No 3.958 8.124 1.173 No
> 1.5 cm 141 57 (40.4) 0.6092° 7.157 15.28 1.292 0.4607
Recurrence
Positive 
(+)
85 37 (43.5) No 42.5 7.778 5.5 No
Negative 
(-)
104 37 (35.5) 0.296° 52 21.21 15 0.5866
Staging Dunn's Multiple Comparison Test 
Difference in rank sum P < 0.05
I 79 25 (31.6) 4.873 13.47 1.516 I vs II -10,44 No
II 39 16 (41) No 6.231 11.45 1.833 No I vs III -3,138 No
III 25 9 (36) 0.2307 3.760 7.055 1.411 0.0725* I vs IV -22,96 No
IV 46 24 (52) 10.39 17.78 2.621 II vs III 7,302 No
II vs IV -12,52 No
III vs IV -19,82 No
°Fisher's exact test
* Kruskal-Wallis testBMC Cancer 2008, 8:220 http://www.biomedcentral.com/1471-2407/8/220
Page 6 of 8
(page number not for citation purposes)
sition (EMT). Key effectors of EMT changes are secreted
proteases that, by dissolving the surrounding ECM mole-
cules, not only create spaces for invading tumour cells to
move, but also mobilize and activate latent growth factors
[12]. Therefore, in recent years special attention has been
given to tumour cell surface-associated proteolytic
enzyme systems such as plasminogen activators and
matrix metalloproteinases [13] because of their impact on
cancer progression and metastasis [12].
Several kinds of evidence strongly implicate a critical role
for uPA-uPAR system in tumour invasion and progression
in different types of human cancer [3-5,7,14-20]. In line
with these data, our immunohistochemical study revealed
a positive correlation between uPAR immunostaining and
increasing tumour differentiation grade. However, a com-
parison of Kaplan-Meier survival curves as a function of
grade revealed statistical significance only for G1 patients.
A valid explanation for this statistical result is quite diffi-
cult based on our incomplete understanding of the molec-
ular mechanisms involved in tumour invasion and
metastasis. However, taking into consideration the signal-
ling tumour – stroma interdependence, contribution of
molecules, including other protease systems, to cancer
aggressiveness can be postulated for cells at various differ-
entiation stages. The total number of proteases made by
mammalian cells is vast and we have just begun to analyze
the actions of only a small portion of them in the context
of cancer pathogenesis. In addition, the expression levels
Prognostic value of uPAR expression Figure 2
Prognostic value of uPAR expression. Kaplan-Meier curves for OSCC patients correlating uPAR expression and overall survival 
(A) (p = 0.0053), survival in grade 1 (B) (p = 0.0447), grade 2 (C) (p = 0.3427) and grade 3 (D) (p = 0.7143) tumours. Dotted 
line, uPAR negative cases ; continuous line, uPAR positive cases.BMC Cancer 2008, 8:220 http://www.biomedcentral.com/1471-2407/8/220
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of uPA in oral tumour tissues require a more detailed
study.
A recent review indicated that uPA-uPAR can interact with
transmembrane proteins to modify multiple signal trans-
duction pathways and influence a wide variety of cellular
behaviours [1]. In particular, in pre-malignant oral kerat-
inocytes, matrix-induced integrin clustering results in the
activation of Src/MEK/ERK signalling, leading to
enhanced uPA expression and re-distribution of uPAR to
sites of clustered integrins [21]. Pericellular matrix prote-
olysis removes physical stimulus for integrin clustering,
leading to loss of integrin signalling and subsequent uPA
expression [1]. Blocking uPAR-α3β1 integrin interaction
using a variety of strategies results in substantially attenu-
ated uPA expression which suggests that uPAR-α3β1 bind-
ing potentiates integrin signalling and subsequent
pericellular proteolysis [22]. Highly invasive OSCC cells
exhibit matrix-independent high-level uPA expression
that is not further responsive to integrin clustering [23].
This indicates that loss of adhesion-regulated proteinase
expression contributes to OSCC invasive potential [1].
Conclusion
Our findings reiterate the concept that increased uPAR
levels may contribute to the spread and invasion of cancer
cells. They also suggest the importance of uPAR as a
potential novel prognostic factor in OSCC. This may be
potentially relevant for the implementation of closer fol-
low-up protocols and/or alternative therapeutic regimens
especially for patients with grade 1 tumours.
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